The non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (also known as Sustiva or Stocrin) is widely used as part of first-line therapy in the UK and many other countries, taken in combination with Truvada, or as part of the combined pill Atripla. Whilst very effective, it is known to have some significant side-effects in a relatively large minority of users. For most, these side-effects diminish after the initial few weeks and disappear or are manageable. A new study has shown that the normal daily dose for efavirenz of 600mg can be reduced by a third with no negative impact on efficacy, but with fewer side-effects.

The full article can be read here.

Please note that this is just a research finding, and not yet a recognised treatment option, and it is strongly recommended that patients should never attempt to change their drug regimen without close involvement of their clinical team.